Xeris Biopharma Holdings Inc
NASDAQ:XERS
Xeris Biopharma Holdings Inc
Revenue
Xeris Biopharma Holdings Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
Revenue
$203.1m
|
CAGR 3-Years
60%
|
CAGR 5-Years
137%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$89.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$63.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$45B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Xeris Biopharma Holdings Inc
Revenue Breakdown
Breakdown by Geography
Xeris Biopharma Holdings Inc
Breakdown by Segments
Xeris Biopharma Holdings Inc
|
Total Revenue:
203.1m
USD
|
|
Product Revenue, Net:
196.6m
USD
|
|
Royalty, Contract And Other Revenue:
6.4m
USD
|
Xeris Biopharma Holdings Inc
Glance View
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
See Also
What is Xeris Biopharma Holdings Inc's Revenue?
Revenue
203.1m
USD
Based on the financial report for Dec 31, 2024, Xeris Biopharma Holdings Inc's Revenue amounts to 203.1m USD.
What is Xeris Biopharma Holdings Inc's Revenue growth rate?
Revenue CAGR 5Y
137%
Over the last year, the Revenue growth was 24%. The average annual Revenue growth rates for Xeris Biopharma Holdings Inc have been 60% over the past three years , 137% over the past five years .
You don't have any saved screeners yet